CCMU
DNTH icon

Cheyne Capital Management (UK)’s Dianthus Therapeutics DNTH Stock Holding History

Cheyne Capital Management (UK)’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,948
Closed -$35.8K – 25
2023
Q2 		$35.8K Hold
2,948
– – 0.13% 19
2023
Q1 		$37.5K Hold
2,948
– – 0.12% 22
2022
Q4 		$18.6K Hold
2,948
– – 0.03% 59
2022
Q3 		$67K Hold
2,948
– – 0.14% 33
2022
Q2 		$57K Hold
2,948
– – 0.05% 78
2022
Q1 		$137K Buy
+2,948
New +$161K 0.09% 100

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Cheyne Capital Management (UK)'s DNTH Position: Q3 2023 in Review

Cheyne Capital Management (UK) sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 2,948 shares — an estimated $35.8K sold.

Cheyne Capital Management (UK) first reported a position in DNTH in Q1 2022 and held it in 6 quarters. The position peaked at $137K in Q1 2022. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

  • Cheyne Capital Management (UK) reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 2,948 Dianthus Therapeutics shares in Q3 2023, an estimated $35.8K.
  • Cheyne Capital Management (UK) first reported a position in Dianthus Therapeutics in Q1 2022 and held it in 6 quarters.
  • Cheyne Capital Management (UK)'s Dianthus Therapeutics position peaked at $137K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q3 2023, filed 27 Oct 2023.